An Open-Label, Flexible-Dose Evaluation of the Safety and Tolerability of STX209 for Treatment of Irritability in Subjects With Autism Spectrum Disorders.

Trial Profile

An Open-Label, Flexible-Dose Evaluation of the Safety and Tolerability of STX209 for Treatment of Irritability in Subjects With Autism Spectrum Disorders.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2013

At a glance

  • Drugs Arbaclofen (Primary)
  • Indications Irritability; Pervasive child development disorders
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 09 Jul 2011 Results were presented at the 42nd Autism Society National Conference.
    • 10 Sep 2010 Status changed from active, no longer recruiting to completed due to reporting of results in a Seaside Therapeutics media release.
    • 09 Sep 2010 Primary endpoint 'Aberrant Behavior Checklist' has been met according to a Seaside Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top